

Table 1. Nerve conduction study findings on upper and lower extremities.

	Stimulation site	Latency (ms)	Amplitude (mV)	Conduction velocity (m/s)
Median motor	right wrist	4.8	13.4	
	elbow	10.5	12.1	44.2
	axilla	14.2	11.0	35.1
Ulnar motor	right wrist	3.2	10.8	
	elbow	8.4	10.0	46.2
	axilla	10.7	9.8	35.7
Peroneal motor	right ankle	6.4	5.2	
	knee	14.6	4.7	35.1
Posterior tibial motor	right ankle	5.2	17.2	
	knee	17.4	11.7	32.2
Median sensory	right F-W	13.3	13.7	36.5
	W-E	5.2	29.3	42.6
	E-Ax	2.7	33.7	45.9
Ulnar sensory	right F-W	3.2	11.2	35.4
	W-E	4.4	23.9	47.7
	E-Ax	2.5	34.7	46.9
Sural sensory	right	4.6	23.9	30.4
	left	4.7	19.5	30.1




Figure 1. Somatosensory evoked potential findings. Prolonged latencies of Erb's, C5 and cortical EPs, and prolonged I-III, III-V and I-V interpeak latencies in left median nerve somatosensory evoked potentials (A), and prolonged latencies of T12 EP and no cortical EP in left posterior tibial nerve somatosensory evoked potentials (B) are seen.

E2, E3, cortisol, ACTH, LH, FSH, total estrogen

, I-III, III-V, I-V (Fig 2).

VLCFA C24:0/22:0 1.229(: 0.628-0.977), C25:0/C22:0 0.082(: 0.012-0.023), C26:0/C22:0 0.040(: 0.003-0.006)

가 가 VLCFA 1.419, 0.049, 0.020 가 (lovas-tatin) 40 mg

(Table 1).

T12 가

가

(Fig. 1).

III, IV, V 가




Figure 2. Brainstem auditory evoked potential findings. Prolonged latencies of III, IV and V EPs and prolonged I-III, III-V and I-V interpeak latencies on left ear with 100dB stimulation (A), and with 115 dB stimulation (B) in left brainstem auditory evoked potentials are seen.

AMN , , Griffin ²
 VLCFA
 가 , 20 ~ 30
 70% , 가 , 가
 peroxisome ALD
 ALD (Adrenoleukodystrophy
 protein, ALDP) , ALDP
 AMN
 가 VLCFA가
 가
 7 , AMN 20
 , HTLV-1 /

N13-N19 가 ,
 P40 ⁶ , I-V
 가
 . 가
 7
 ,
 8
 VLCFA
 가 ⁹
 , VLCFA
 가
 가
 VLCFA ¹⁰
 , thalidomide
 ,
 VLCFA AMN
 가 .
 AMN
 31
 1 .

REFERENCES

1. Suk SH, Sohn YH, Choi YC, Kim JS. A case of adrenomyeloneuropathy. *J Korean Neurol Assoc* 1991;9(2):262-268.
2. Griffin JW, Goren E, Schaumburg H, Engel WK & Loriaux L. Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. *Neurology* 1977;27:1107-1113.
3. Brennemann W, Kohler W, Zierz S, Klingmuller D. Occurrence of adrenocortical insufficiency in adrenomyeloneuropathy. *Neurology* 1996;47(2):605.
4. Moser HW, Kemp S, Smith KD. Mutational analysis and the pathogenesis of variant X-linked adrenoleukodystrophy phenotypes. *Arch Neurol* 1999;56:273-275.
5. Assies J, Gooren LJG, van geel B, Barth PG. Signs of testicular insufficiency in adrenomyeloneuropathy and neuro-

- logically asymptomatic X-linked adreno leukodystrophy: a retrospective study. *Int J Androl* 1997;20(5):315-321.
6. Kaplan PW, Tusa RJ, Rignani JB, Moser HW. Somatosensory evoked potentials in adrenomyeloneuropathy. *Neurology* 1997;48:1662-1667.
 7. Chaudhry V, Moser HW, Cornblath DR. Nerve conduction studies in adrenomyeloneuropathy. *J Neuro Neurosurg Psychiatry* 1996;61(2):181-185.
 8. Edwin D, Speedie LJ, Kohler W, Naidu S, Kruse B, Moser HW. Cognitive and brain Magnetic Resonance Imaging Findings in adrenomyeloneuropathy. *Ann Neurol* 1996; 40:675-678.
 9. Moser AB, Kreiter N, Bezman L, Lu S, Raymond GV, Naidu S et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. *Ann Neurol* 1999;45:100-110.
 10. Singh I, Khan M, Key L, Pai S. Lovastatin for X-Linked Adrenoleukodystrophy. *N Engl J Med* 1998;339(10):702-703.